Pfizer taps Boltz for AI drug design; Medtronic wires AI into surgery

The article frames these two developments against a backdrop of runaway demand for AI data centers, illustrated by Nvidia's US$5.7t market cap milestone. That capital flow is now reaching healthcare, where the ability to crunch medical data, scan images, and support virtual care at global scale is starting to reshape how companies operate.

Pfizer and Medtronic represent two distinct entry points. Pfizer, a global biopharma giant with about US$63.7b in Global Biopharmaceuticals Business revenue and a roughly US$160.3b valuation, is pushing into biomolecular AI alongside Boltz, aiming at how molecules are designed and advanced. Medtronic, a US$110.6b medical device heavyweight, draws most of its revenue from Cardiovascular at US$14.6b, followed by Neuroscience at US$10.5b and Medical Surgical at US$9.0b, where its AI surgical video and analytics platform sits. Together they show AI moving from edge tools into the core of drug discovery and surgical care.

For investors and industry watchers, the stakes hinge on execution rather than announcements. Whether Pfizer's AI work shortens the path from lab to patient, and whether Medtronic's operating-room intelligence improves procedural outcomes, will depend on clinical validation and integration into existing workflows. That is the gap between early AI programs and measurable long-term impact.